News | July 03, 2012

Abbreviated ECHO/ECG Protocol Might Protect Young Athletes

July 3, 2012 — While rare, when sudden cardiac death occurs in a seemingly healthy competitive young athlete, the societal loss is high. At a time when the world is battling obesity in epidemic proportions, fear should not affect how parents view athletic participation. A recent study, to be presented at the American Society of Echocardiography (ASE) 23rd Annual Scientific Sessions, June 27 to July 3, 2012, at the Gaylord National in National Harbor, Md., suggests an abbreviated echocardiographic profile may potentially help identify young athletes at risk for sudden cardiac death and to help athletes, their physicians and families make better decisions about full participation in athletic activities. A poster based on the study was displayed July 1. 

“The primary causes of sudden cardiac death are anatomic anomalies, and abnormalities of the muscular and electrical systems. Present athletic screening involves the taking of a thorough personal and family history, physical examination, and, if indicated, further cardiac testing. While ideal, the addition of EKG and echocardiography to every screening examination is extremely time-consuming and is currently cost-prohibitive. In our study, we designed a protocol which allows a less costly, abbreviated echocardiogram as well as EKG in a mass screening scenario. The goal is to provide more a more complete data set which is cost-effective to care providers, who may then better counsel athletes and their families on full participation in sports. While the cost-effectiveness and impact on the rate reduction of sudden cardiac death are not yet known, the impact on quality of life in reassurance of cardiac health during exercise is priceless,” said Michelle A. Grenier, lead investigator on the study. Robert Hinton, Timothy J. Knilans, John L. Jefferies, Wayne Mays, Nicholas Edwards, Jeffrey Towbin, Richard Czosek, and Jeffery Anderson, all of Cincinnati Children’s Hospital Medical Center in Cincinnati, Ohio, were also part of the research team.

The study found that the number of patients with clinically silent aortopathy and myocardial abnormalities appears disproportionately high in these active athletic adolescents. The abbreviated echo format allows for rapid screening of athletes as part of a general sports screening. The impact of early identification and intervention strategies, as well as screening of at risk, first-degree relatives, is not known, but suggests the utility of echo in detecting aortic and myocardial pathology. The risk of these abnormalities having gone undetected is not known. 
 

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init